Tomasz M. Beer, MD
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Deputy Director, OHSU Knight Cancer Institute
Oregon Health & Science University
Additional Content Development Faculty
Robert Dreicer, MD, MS, MACP, FASCO
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Elisabeth Heath, MD, FACP
Hartmann Endowed Chair for Prostate Cancer Research
Professor of Oncology and Medicine
Genitourinary Multidisciplinary Team Leader
Director, Prostate Cancer Research
Associate Center Director for Translational Sciences
Karmanos Cancer Institute
Wayne State University School of Medicine
For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic prostate cancer and be aware that management of patients with fewer than 5 metastases is different from that of patients with polymetastatic disease. Recommendations for the initial management of patients with hormone-naïve polymetastatic disease are also changing. Patients with metastatic castration-resistant prostate cancer have many new treatment options, but clinicians have little guidance on initial selection or sequencing of these agents. This activity will examine evolving best practices in mPRCA.
Medical oncologists, radiation oncologists, surgical/urological oncologists, NPs, PAs, oncology nurses, and other clinicians involved in the care of patients with metastatic prostate cancer.
Upon completion of this educational activity, the participant should be able to:
- Discuss evidence-based approaches to optimizing care for patients with oligometastatic hormone-sensitive prostate cancer.
- Describe evidence-based management of patients with polymetastatic hormone-sensitive prostate cancer.
- Summarize evidence-based recommendations for the management of patients with metastatic hormone-resistant prostate cancer.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Beer is a consultant/advisor to AbbVie, Clovis Oncology, and Janssen Japan; has stock ownership in Salarius Pharmaceuticals; and has received research grants from Astellas, Boehringer Ingelheim, BMS, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Pfizer, Sotio, and Theraclone Sciences/OncoResponse.
Dr. Dreicer is a consultant/advisor to Asana, Astellas, AstraZeneca, BMS, EMD, Exelixis, Genentech/Roche, Janssen Orion, Sanofi Genzyme, and Serono/Pfizer.
Dr. Heath serves on the speakers bureaus of Sanofi and Agensys; and has received research grants from Tokai, SeaGen, Agensys, Dendreon, Genentech, Millennium, Celldex, Inovio, and Celgene.
Penn State staff involved in the development and review of this activity have nothing to disclose.
MCM Education staff involved in the development and review of this activity have nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6193-18-T.
Commercial Support Statements
Supported by independent educational grants from Sanofi Genzyme; Bayer Healthcare Pharmaceuticals, Inc.; and AbbVie Inc.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Sanofi Genzyme; Bayer Healthcare Pharmaceuticals, Inc.; or AbbVie Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.